SHNXY (Shandong Xinhua Pharmaceutical Co) Piotroski F-Score: 5 (As of Jul. 08, 2026) — 17% Below Median


SHNXY Shandong Xinhua Pharmaceutical Co Ltd SHNXY
75 GF Score
Price $18.19
GF Value $21.89
! 5 Warning Signs
View Full Analysis

What is Shandong Xinhua Pharmaceutical Co Piotroski F-Score?

Shandong Xinhua Pharmaceutical Co SHNXY 75 Piotroski F-Score is 5 as of Jul. 08, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates SHNXY with a GF Score™ of 75/100 and a GF Value™ of $21.89. The stock has 5 warning signs investors should review. Among 980 Drug Manufacturers companies, Shandong Xinhua Pharmaceutical Co ranks better than 61.22% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shandong Xinhua Pharmaceutical Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Shandong Xinhua Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

SHNXY' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Shandong Xinhua Pharmaceutical Co was 8. The lowest was 3. And the median was 6.

Shandong Xinhua Pharmaceutical Co  (OTCPK:SHNXY) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shandong Xinhua Pharmaceutical Co Piotroski F-Score Related Terms


Shandong Xinhua Pharmaceutical Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Shandong Xinhua Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Xinhua Pharmaceutical Co Piotroski F-Score Chart

Shandong Xinhua Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 6.00 6.00 4.00 6.00

Shandong Xinhua Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 5.00 5.00 6.00 5.00

SHNXY vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Xinhua Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Xinhua Pharmaceutical Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Xinhua Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shandong Xinhua Pharmaceutical Co's Piotroski F-Score falls into.


SHNXY
75GF Score
Shandong Xinhua Pharmaceutical Co Ltd SHNXY
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 15.551 + 4.557 + 4.78 + 12.174 = $37 Mil.
Cash Flow from Operations was 31.434 + 12.335 + 30.062 + -16.911 = $57 Mil.
Revenue was 307.64 + 298.142 + 282.84 + 351.569 = $1,240 Mil.
Gross Profit was 66.014 + 51.516 + 49.414 + 64.002 = $231 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(1278.724 + 1286.51 + 1276.583 + 1304.194 + 1315.844) / 5 = $1292.371 Mil.
Total Assets at the begining of this year (Mar25) was $1,279 Mil.
Long-Term Debt & Capital Lease Obligation was $137 Mil.
Total Current Assets was $588 Mil.
Total Current Liabilities was $333 Mil.
Net Income was 17.027 + 11.119 + 17.298 + 15.463 = $61 Mil.

Revenue was 311.217 + 282.884 + 237.909 + 335.181 = $1,167 Mil.
Gross Profit was 69.69 + 56.204 + 63.084 + 62.838 = $252 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1175.863 + 1203.89 + 1247.085 + 1238.837 + 1278.724) / 5 = $1228.8798 Mil.
Total Assets at the begining of last year (Mar24) was $1,176 Mil.
Long-Term Debt & Capital Lease Obligation was $55 Mil.
Total Current Assets was $552 Mil.
Total Current Liabilities was $446 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shandong Xinhua Pharmaceutical Co's current Net Income (TTM) was 37. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shandong Xinhua Pharmaceutical Co's current Cash Flow from Operations (TTM) was 57. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=37.062/1278.724
=0.02898358

ROA (Last Year)=Net Income/Total Assets (Mar24)
=60.907/1175.863
=0.0517977

Shandong Xinhua Pharmaceutical Co's return on assets of this year was 0.02898358. Shandong Xinhua Pharmaceutical Co's return on assets of last year was 0.0517977. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shandong Xinhua Pharmaceutical Co's current Net Income (TTM) was 37. Shandong Xinhua Pharmaceutical Co's current Cash Flow from Operations (TTM) was 57. ==> 57 > 37 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=136.831/1292.371
=0.10587594

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=55.11/1228.8798
=0.04484572

Shandong Xinhua Pharmaceutical Co's gearing of this year was 0.10587594. Shandong Xinhua Pharmaceutical Co's gearing of last year was 0.04484572. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=587.892/333.246
=1.7641382

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=551.694/446.224
=1.23636111

Shandong Xinhua Pharmaceutical Co's current ratio of this year was 1.7641382. Shandong Xinhua Pharmaceutical Co's current ratio of last year was 1.23636111. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shandong Xinhua Pharmaceutical Co's number of shares in issue this year was 69.919. Shandong Xinhua Pharmaceutical Co's number of shares in issue last year was 74.73. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=230.946/1240.191
=0.18621809

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=251.816/1167.191
=0.21574532

Shandong Xinhua Pharmaceutical Co's gross margin of this year was 0.18621809. Shandong Xinhua Pharmaceutical Co's gross margin of last year was 0.21574532. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=1240.191/1278.724
=0.96986605

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1167.191/1175.863
=0.99262499

Shandong Xinhua Pharmaceutical Co's asset turnover of this year was 0.96986605. Shandong Xinhua Pharmaceutical Co's asset turnover of last year was 0.99262499. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shandong Xinhua Pharmaceutical Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Shandong Xinhua Pharmaceutical Co (SHNXY) has a Piotroski F-Score of 5 as of Jul. 08, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shandong Xinhua Pharmaceutical Co and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, Shandong Xinhua Pharmaceutical Co's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Shandong Xinhua Pharmaceutical Co ranks #380 out of 980 companies in the Drug Manufacturers industry, placing it in the top 38.8%.
Is Shandong Xinhua Pharmaceutical Co's Piotroski F-Score too high?
Shandong Xinhua Pharmaceutical Co's current Piotroski F-Score of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Shandong Xinhua Pharmaceutical Co's value of 5 is 0% at this industry median. Based on the distribution chart, Shandong Xinhua Pharmaceutical Co ranks #380 out of 980 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shandong Xinhua Pharmaceutical Co has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Xinhua Pharmaceutical Co's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shandong Xinhua Pharmaceutical Co ranks #380 out of 980 companies for Piotroski F-Score. This puts Shandong Xinhua Pharmaceutical Co in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Shandong Xinhua Pharmaceutical Co's value of 5 is 0% at this benchmark. Historically, Shandong Xinhua Pharmaceutical Co's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Shandong Xinhua Pharmaceutical Co has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Xinhua Pharmaceutical Co's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Shandong Xinhua Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Xinhua Pharmaceutical Co's current Piotroski F-Score is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Xinhua Pharmaceutical Co stock overvalued right now?
Shandong Xinhua Pharmaceutical Co (SHNXY) has a current Piotroski F-Score of 5. The stock's GF Value™ is $21.89, compared to a current price of $18.19 — trading 16.9% below its estimated fair value. The current Piotroski F-Score is 5, which is 17% below median its 10-year median of 6.00 and 0% at the Drug Manufacturers industry median of 5.00. Shandong Xinhua Pharmaceutical Co's overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Shandong Xinhua Pharmaceutical Co (SHNXY), the current Piotroski F-Score is 5 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Xinhua Pharmaceutical Co (SHNXY) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Xinhua Pharmaceutical Co stock appears to be undervalued. The current stock price of $18.19 is trading 16.9% below its estimated GF Value™ of $21.89.

Key valuation signals for SHNXY:

  • Piotroski F-Score: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: $21.89 vs. price of $18.19 (16.9% below fair value)
  • GF Score™: 75/100 with 5 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#380 of 980)

No single metric tells the full story. See the SHNXY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shandong Xinhua Pharmaceutical Co Business Description

Address No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo, Shandong, CHN, 255086
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates various segments namely Chemical raw materials, Preparations, Pharmaceutical intermediates and other products. The company is mainly engaged in the business of development, manufacture and sale of bulk pharmaceuticals, preparations and chemical products.
75GF Score

Get the complete analysis for SHNXY

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.19
Price
$21.89
GF Value